PubRank

A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

Clinical Trial ID NCT01021059

PubWeight™ 28.74‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01021059

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006 6.22
2 The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999 3.81
3 Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001 3.45
4 Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 2011 1.82
5 Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2011 1.64
6 Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 2012 1.41
7 Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 2014 1.38
8 Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012 1.19
9 Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol 2011 1.09
10 Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood 2012 1.02
11 The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect 2011 1.01
12 Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014 0.95
13 Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014 0.94
14 Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy. Cell Mol Immunol 2012 0.93
15 Natural killer cell-based therapies. F1000 Med Rep 2011 0.93
16 Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 2011 0.92
17 The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res 2015 0.91
18 Molecular pathways: interleukin-15 signaling in health and in cancer. Clin Cancer Res 2014 0.90
19 Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy 2011 0.88
20 Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway. PLoS One 2012 0.85
21 Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One 2012 0.85
22 The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev 2015 0.84
23 Overexpression of IL-15 promotes tumor destruction via NK1.1+ cells in a spontaneous breast cancer model. BMC Cancer 2015 0.83
24 IL-15 Agonists: The Cancer Cure Cytokine. J Mol Genet Med 2013 0.82
25 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
26 IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. Cancer Res 2015 0.81
27 Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med 2012 0.80
28 Renal Cancer Stem Cells: Characterization and Targeted Therapies. Stem Cells Int 2016 0.80
29 Transmembrane-Bound IL-15-Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt/GSK-3β/β-Catenin Pathway. Neoplasia 2015 0.78
30 Redirecting the immune response: role of adoptive T cell therapy. Hum Gene Ther 2010 0.77
31 High-density lipoproteins delivering interleukin-15. Oncoimmunology 2013 0.75
32 KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance. Oncoimmunology 2014 0.75
33 Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. Front Pharmacol 2016 0.75
Next 100